Sponsor Pipeline

Plus Therapeutics Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
3
Recruiting
1
Disease Areas
Active Trials by Phase
Phase 1/2
1
Phase 1
4
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT01906385 Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma… Glioma Recruiting
Phase 1
NCT05460507 Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who… Glioma Recruiting
NCT07098806 Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for… Leptomeningeal Metastasis Recruiting
NCT05034497 Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases Leptomeningeal Metastasis Active, Not Recruiting
NCT07061626 Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in… Ependymoma Not Yet Recruiting
Disease Areas
Glioma (3)
Get alerts when Plus Therapeutics's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free